Akèy › Maladi kadyovaskilè › Texas › Amarillo
Etid klinik pou Maladi kadyovaskilè nan Amarillo, TX
5 etid pou Maladi kadyovaskilè ap chèche patisipan nan sit nan ak bò kote Amarillo (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Ap rekriteFaz 4
- PharmaTex Research, Amarillo
- Amarillo Heart Clinical Research Institute, Inc., Amarillo
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Ap rekriteFaz 3
- Clinical Trial Site, Amarillo
- Clinical Trial Site, Amarillo
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
Ap rekriteFaz 3
- Research Site, Amarillo
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Ap rekriteFaz 3
- PharmaTex Research, LLC, Amarillo
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Ap rekriteFaz 3
- PharmaTex Research LLC, Amarillo
Etid Maladi kadyovaskilè nan lòt vil
- Boston, MA37 etid
- New York City, NY33 etid
- Washington, DC29 etid
- Houston, TX24 etid
- Dallas, TX23 etid
- Atlanta, GA22 etid
- Cleveland, OH22 etid
- Chicago, IL21 etid
- Philadelphia, PA21 etid
- Pittsburgh, PA20 etid
- St. Louis, MO20 etid
- San Francisco, CA18 etid
Lòt etid nan Amarillo
- Obèsite10 etid
- Ensifizyans kadyak8 etid
- Kansè Poumon ki pa ti selil8 etid
- Sipwa7 etid
- Ateroskleroz6 etid
- Kansè poumon5 etid
- Kayò san4 etid
- Fibrilasyon atriyal3 etid
- Maladi Dijestif3 etid
- Kansè kolorektal3 etid
- Kansè nan tete3 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.